Embera NeuroTherapeutics
Embera NeuroTherapeutics is developing EMB-001, a medication aimed at treating addiction by moderating the stress response system, currently advancing through clinical trials for cocaine use disorder and smoking cessation.
Company Overview
Embera NeuroTherapeutics is a pioneering pharmaceutical company focused on developing the first medication to treat addiction by addressing the stress response system. The company's primary product, EMB-001, aims to reduce cravings and loss of control by targeting multiple neurological pathways.
Innovative Treatments for Addiction
Embera NeuroTherapeutics is at the forefront of addiction treatment with its flagship product, EMB-001. This patented combination therapy includes two FDA-approved medications: metyrapone and oxazepam. Studies indicate that EMB-001 can significantly reduce cocaine use and shows promise in smoking cessation, offering a novel approach to treating these addictive behaviors.
Clinical Trials and Research
Embera NeuroTherapeutics has completed various clinical studies to evaluate the efficacy and safety of EMB-001. These include a completed Phase 1 safety and pharmacokinetics study in smokers and a pilot clinical study showing significantly reduced cocaine use. The company has advanced EMB-001 into Phase 2 clinical studies for cocaine use disorder and smoking cessation.
Funding and Collaborations
The company has successfully secured funding to support its clinical development programs. Embera received a Series B financing to advance EMB-001 and an $11.1 million grant from the National Institute on Drug Abuse (NIDA) for the treatment of cocaine addiction. Embera is also focused on developing partnerships to optimize the development of its treatments.
Research Presentations and Scientific Contributions
Embera NeuroTherapeutics actively engages with the scientific community by presenting its research at significant conferences. The company has shared findings at the Society for Research of Nicotine and Tobacco (SRNT) Annual Meeting and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, demonstrating the relevance and impact of its work.